ALiEM - Pharm Pearls
AUGUST 7, 2023
A 10-year-old male with no past medical history presents to the Emergency Department (ED) by EMS for evaluation of an injury sustained while playing tackle football. The patient was forcibly hit by another child against a tree. He complains of sharp right shoulder and chest pain that worsens with movement of his right upper extremity and he arrives wearing a sling to immobilize the arm.
STAT
AUGUST 7, 2023
When faced with a new diagnosis, a patient knows that the necessary treatment may make her feel lousy. What she doesn’t always account for, though, is the effect that it will have on the rest of her life. It’s common for patients and physicians to decide whether a treatment is worth it by weighing the health benefits against the side effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
AUGUST 7, 2023
Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat autism, anxiety and more.
STAT
AUGUST 7, 2023
There are many period products on the market from pads, tampons and cups to discs. Yet, there is a dearth of reliable information about how much menstrual blood they can hold — a useful metric for clinicians as well as consumers. Heavy menstrual bleeding affects up to a third of people who menstruate and that can only be diagnosed using traditional menstrual products like pads and tampons.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
AUGUST 7, 2023
Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.
STAT
AUGUST 7, 2023
Ariel Brigham was drowning. Hurricane Harvey had dumped over 50 inches of rain across Houston and coastal Texas, leaving the then-26-year-old Texan stranded in her flooded apartment. But what was killing Brigham wasn’t water from the hurricane. It was the excess fluid and toxins building up in her own body.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
STAT
AUGUST 7, 2023
NEW YORK — A nurse supervisor at Montefiore Comprehensive Health Care Center in the Bronx was delivering her start-of-shift updates and mantras — “Covid is not finished with us … clean, clean, clean!”— to the clinicians and administrative staff bunched up nearby. Hawa Abraham, not one or the other, stood among them.
Pharmaceutical Commerce
AUGUST 7, 2023
Creating a user-centric approach that harnesses both digital tools and behavioral science is key to getting—and maintaining—patients on therapy, and improving clinical, financial, and, ultimately, brand-success outcomes for pharma manufacturers.
STAT
AUGUST 7, 2023
Word spread through an Oregon hospital last month that a visitor was causing trouble in the maternity ward, and nurses were warned the man might try to abduct his partner’s newborn. Hours later, the visitor opened fire, killing a security guard and sending patients, nurses and doctors scrambling for cover.
PharmExec
AUGUST 7, 2023
Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways companies can remain accountable for DE&I efforts in pharma in this Pharmaceutical Executive Podcast video.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
AUGUST 7, 2023
Recently, after years of pressure, advocates including author and philanthropist John Green scored victory against Johnson & Johnson over a patent on a key tuberculosis drug. The campaigners hope the move will give millions of people affected by tuberculosis in low- and middle-income countries access to the lifesaving medication bedaquiline. But the drugs alone can’t win the fight against the debilitating disease.
Drug Patent Watch
AUGUST 7, 2023
A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings involving Orange Book and biologic patents, based… The post Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends appeared first on DrugPatentWatch - Make Better Decisions.
STAT
AUGUST 7, 2023
Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-so familiar routine of online meetings, calls, and deadlines has predictably returned, But what can you do? The world, such as it is, continues to spin. So to cope, we are brewing cups of stimulation — our choice today is cinnamon hazelnut.
BioPharma Dive
AUGUST 7, 2023
The need for more research into rare diseases is clear, but researchers face significant challenges. Fortunately, technology has created opportunities to innovate in clinical trials for rare diseases.
STAT
AUGUST 7, 2023
Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder. On Friday, the agency granted market clearance for the drug , called Zurzuvae, to treat women with postpartum depression, a smaller commercial market.
Express Pharma
AUGUST 7, 2023
A promising shift towards the development of antibody-drug conjugates (ADC) for cancer treatment is taking place in the pharma industry. A recent look at the marketed and pipeline drugs shows that Daiichi Sankyo, Seagen, and Roche are three of the most important companies in this wave. Daiichi’s recent trial results suggest that the company will continue to remain dominant in the oncology ADC market, says GlobalData.
STAT
AUGUST 7, 2023
A behind-the-scenes feud over a drug development program erupted into public view as Nektar Therapeutics filed a lawsuit accusing Eli Lilly of undermining a project in favor of another deal. At issue is a partnership that began in 2017 to develop and potentially market a drug, known as Rezpeg, to treat various autoimmune diseases, and in particular, eczema.
Outsourcing Pharma
AUGUST 7, 2023
The first oral pill in the United States specifically for postpartum depression, a serious mental illness, has been approved by the US Food and Drug Administration (FDA).
Express Pharma
AUGUST 7, 2023
Marksans has announced that the United State Food and Drug Administration (US FDA) has completed a post-marketing adverse drug experience (PADE) inspection. The inspection closed with two observations. The inspection was conducted at its Goa, Vema manufacturing facility from July 31, 2023 to August 4, 2023. The inspection included comprehensive scrutiny of practices and procedures for reporting of adverse events of Marksans’ marketed products.
European Pharmaceutical Review
AUGUST 7, 2023
Astellas Pharma has agreed to invest a total of $50 million for the right to license P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumour indications. Under the agreement, the company will acquire approximately 8.8 percent of Poseida Therapeutics. Astellas Pharma will receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1.
BioPharma Dive
AUGUST 7, 2023
The investment bank estimates that, while many smaller biotechs are laying off staff, larger companies are still growing from early 2021 levels.
Pharma Times
AUGUST 7, 2023
Partnership with Icahn School of Medicine will involve developing exoAAV vectors for heart disease patients - News - PharmaTimes
Express Pharma
AUGUST 7, 2023
Nobody is likely to have a difference of opinion that the medical system and the processes have evolved as a result of knowledge, necessity and the prevailing medicines and antidotes available in different regions. This is true for the whole world whether it is America, Japan, China, Europe, India, the Amazon or wilds of Africa. The diseases and abnormalities with the human body (animals as well) are not new.
Pharma Times
AUGUST 7, 2023
A combination of zipalertinib and chemotherapy will be evaluated as a treatment for adults - News - PharmaTimes
Pharmaceutical Technology
AUGUST 7, 2023
Health Canada has granted approval for GSK’s Arexvy vaccine to prevent RSV-caused lower respiratory tract disease in older adults.
European Pharmaceutical Review
AUGUST 7, 2023
For the first-time, researchers have successfully and safely produced the antibiotic cefazolin using continuous-flow manufacturing. While usually produced via batch manufacturing , this latter process is time-consuming, requires specialised equipment results in a large amount of waste. On the other hand: “The method we have developed can cover mass production within compact manufacturing facilities, does not incur huge equipment costs, and can provide a pharmaceutical-grade drug safely and secur
Pharmaceutical Technology
AUGUST 7, 2023
Iveric Bio, an Astellas company, has received clearance from the US Food and Drug Administration (FDA) for IZERVAY.
European Pharmaceutical Review
AUGUST 7, 2023
The US Food and Drug Administration ( FDA ) has approved Zurzuvae ( zuranolone ), the first oral medicine to treat postpartum depression (PPD) in adults. Historically, treatment for PPD has been only available as an IV injection. “The FDA approval of Zurzuvae to treat postpartum depression is a major milestone for the hundreds of thousands of women who experience this underdiagnosed and undertreated condition,” commented Christopher Viehbacher, President and Chief Executive Officer at Biogen.
Pharmaceutical Technology
AUGUST 7, 2023
Following the approval, Biogen plans for the commercial launch Zurzuvae (zuranolone) in the last quarter of 2023.
Pharmaceutical Commerce
AUGUST 7, 2023
How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.
assurecare
AUGUST 7, 2023
Prior authorization is a crucial process in healthcare that demands healthcare providers to acquire approval from insurance companies before a treatment, procedure, or prescription can be covered. This process is formed to ensure medical requirements are met and is essential for managing costs and providing appropriate care. Nonetheless, prior authorization can be time-consuming, complicated, and expensive for healthcare providers, as they often have to pay organizational fees to process request
Pharmaceutical Technology
AUGUST 7, 2023
HuidaGene claims its gene therapy candidate was superior to FDA-approved Luxturna in preclinical studies.
World Pharma News
AUGUST 7, 2023
The U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities.
PharmExec
AUGUST 7, 2023
Decision comes amid recommendation from agency’s Committee for Medicinal Products for Human Use.
The Pharmacist
AUGUST 7, 2023
The Company Chemists’ Association (CCA) has called for more stringent action on distance selling pharmacies that supply a predominantly local area, after new research suggested more than 70% were not following contractual requirements. Many patients choose to order their prescriptions through a distance selling pharmacy (DSP), which is required by NHS England (NHSE) to make […] The post CCA urges action on ‘pseudo’ distance selling pharmacies appeared first on The Pharmacist.
Expert insights. Personalized for you.
246 
Let's personalize your content